The Hospital for Special Surgery in New York presented data from the first U.S. study of BONESUPPORT's CERAMENT with Gentamicin in an infected rat model at the European Bone & Joint Infection Society.
Here are five observations:
1. The comparative evaluation study analyzed the improvement of new bone growth and reduction in infection rate after debridement in a rat osteomyelitis model. The study compared the use of CERAMENT|G to the use of CERAMENT|BONE VOID FILLER without antibiotics to the use of no void filler.
2. The CERAMENT|G exhibited no infection and greater new bone growth at six months, compared to the other two groups.
3. Mathias P. Bostrom, MD, HSS, said the study supports CERAMENT|G as available void filler for managing osteomyelitis.
4. CERAMENT|G received CE-mark in 2013 and is in the process of obtaining FDA clearance. It is the first antibiotic eluting bone substitute intended to protect bone healing in osteomyelitis management.
5. BONESUPPORT, headquartered in Lund, Sweden, develops injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation.